Overview
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
Status:
Completed
Completed
Trial end date:
2013-05-01
2013-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This was an 18-month, multi-center, open-label, clinical extension study. Patients completing earlier second extension studies (CACZ885H2356E2 and CACZ885H2357E2) continued to be treated in this combined extension 3 study for any new gouty arthritis flare on demand with one subcutaneous (s.c.) injection of canakinumab 150 mg.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis PharmaceuticalsTreatments:
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Criteria
Inclusion Criteria:- Patients who have completed the second extension studies CACZ885H2356E2 or
CACZ885H2357E2
- Patients treated with canakinumab in the core studies or subsequent extensions
Exclusion Criteria:
- Pregnant or nursing (lactating) women